


1619



FORM PTO-1449

Att. Docket No.: REG 900A

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

USSN : 10/055,842

Applicant: Gale, N.W., et al.

Date Filed: January 23, 2002

Title: Methods of Imaging and Targeting
Vasculature

Examiner: Not yet known

Group Art Unit: 1619

February 6, 2003

U.S. PATENT DOCUMENTS

<u>Examiner Initials</u>	<u>Patent Number</u>	<u>Issue Date</u>	<u>Publication Number</u>	<u>Publication Date</u>	<u>Name</u>
------------------------------	--------------------------	-----------------------	-------------------------------	-----------------------------	-------------

FOREIGN PATENT DOCUMENTS

<u>Examiner Initials</u>	<u>Document Number</u>	<u>Date</u>	<u>Country</u>	<u>Class/ Date Subclass</u>	<u>Translation Yes No</u>
------------------------------	----------------------------	-------------	----------------	---------------------------------	-------------------------------

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, etc.)

- ____ Kirsch, JE, 1991, "Basic principles of magnetic resonance contrast agents", Top Magn Reson Imaging 3:1-18
- ____ Wallis, F. and Gilbert, FJ, 1999, J R, "Magnetic resonance imaging in oncology: an overview", Coll Surg Edinb 44:117-125
- ____ Schiepers, C. and Hoh, CK, 1998, "Positron emission tomography as a diagnostic tool in oncology", Eur Radiol 8:1481-1494
- ____ Ferrand, SK, et al., 1999, "What is new in nuclear medicine imaging?", Surg Oncol Clin N Am 8:185-204
- ____ Wang, H.U., et al., 1998, "Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4", Cell 93:741-753.

RECEIVED
FEB 14 2003
TECH CENTER 1600/2900

____ Gerety, S.S., et al., 1999, "Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development", Mol Cell 4:403-414.

____ Adams, R.H., et al., 1999, "Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis", Genes & Dev 13:295-306.

EXAMINER
CONSIDERED


DATE

EXAMINER:

Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Respectfully submitted,

By:



Linda O. Palladino

Reg. No. 45,636

Agent for Applicants

Regeneron Pharmaceuticals, Inc.

777 Old Saw Mill River Road

Tarrytown, New York 10591

(914) 345-7400